Advertisement

International Journal of Clinical Pharmacy

, Volume 35, Issue 3, pp 306–308 | Cite as

Vocal cord paralysis during the treatment of mantle cell lymphoma with vincristine

  • Serkan Feyyaz Yalin
  • Sinan Trabulus
  • Ayse Serap Yalin
  • Gulsah Yenidunya Yalin
  • Seniz Ongoren
  • Mehmet Riza AltiparmakEmail author
Case Report

Abstract

Case description We present a case of a seventy-eight year-old man who developed vocal cord paralysis without any sign of peripheral neuropathy during the treatment of Mantle Cell Lymphoma. He first presented in 2008 with a few bilateral small inguinal lymph nodes. Inguinal lymph node biopsy demonstrated Mantle Cell Lymphoma. Flow cytometry studies of peripheral blood and bone marrow cells were compatible with Mantle Cell Lymphoma. R-CHOP chemotherapy triweekly (Rituximab; Cyclophosphamide; Adriamycin; Vincristine; and Methylprednisolone) was planned. At the end of the second cycle, the patient complained of hoarseness without any symptoms of dysphagia or odynophagia. Direct flexible laryngoscopy showed bilateral vocal cord paralysis. Vincristine was discontinued and the patient’s voice gradually resolved in about 4 months. Conclusion Vincristine may cause peripheral, autonomic and cranial neuropathies. However cranial nerve involvement is quite uncommon.

Keywords

Cranial neuropathy Mantle cell lymphoma Neurotoxicity Vincristine Vocal cord paralysis 

Notes

Conflicts of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Sahenk Z, Brady ST, Mendell JR. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve. 1987;10:80–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Green LS, Donoso JA, Heller-Bettinger IE, Samson FE. Axonal transport disturbances in vincristine-induced peripheral neuropathy. Ann Neurol. 1977;1(3):255–62.PubMedCrossRefGoogle Scholar
  3. 3.
    Oakes SG, Santone KS, Powis G. Effect of some anticancer drugs on the surface membrane electrical properties of differentiated murine neuroblastoma cells. J Natl Cancer Inst. 1987;79:155–61.PubMedGoogle Scholar
  4. 4.
    Chauvenet AR, Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B. Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-Tooth disease in acute lymphoblastic leukemia: a pediatric oncology group study. J Pediatr Hematol Oncol. 2003;25(4):316–20.PubMedCrossRefGoogle Scholar
  5. 5.
    Bradley WG, Lassman LP, Pearce GW, Walton JN. The neuromyopathy of vincristine in man: clinical, electrophysiological, and pathological studies. J Neurol Sci. 1970;10(2):107–31.PubMedCrossRefGoogle Scholar
  6. 6.
    Sahenk Z, Brady ST, Mendell JR. Studies on the pathogenesis of vincristine induced neuropathy. Muscle Nerve. 1987;10(1):80–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev. 1994;20(2):191–214.PubMedCrossRefGoogle Scholar
  8. 8.
    Bohannon RA, Miller DG, Diamond HD. Vincristine in the treatment of lymphomas and leukemia. Cancer Res. 1963;23:613–21.PubMedGoogle Scholar
  9. 9.
    Bay A, Yilmaz C, Yilmaz N, Oner AF. Vincristine induced cranial polyneuropathy. Indian J Pediatr. 2006;73:531–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.PubMedCrossRefGoogle Scholar
  11. 11.
    Kuruvilla G, Perry S, Wilson B, El-Hakim H. The natural history of vincristine-induced laryngeal paralysis in children. Arch Otolaryngol Head Neck Surg. 2009;135(1):101–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Naithani R, Dolai TK, Kumar R. Bilateral vocal cord paralysis following treatment with vincristine. Indian Pediatr. 2009;46(1):68–9.PubMedGoogle Scholar
  13. 13.
    Latiff ZA, Kamal NA, Jahendran J, Alias H, Goh BS, Syed Zakaria SZ, et al. Vincristine-induced vocal cord palsy: case report and review of the literature. J Pediatr Hematol Oncol. 2010;32(5):407–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Farruggia P, Tropia S, Cannella S, Bruno G, Oddo G, D’Angelo P. Vocal cord palsy after vincristine treatment in a child and the inefficacy of glutamic acid in the prevention of relapse: a case report. J Med Case Rep. 2012;6(1):128.PubMedCrossRefGoogle Scholar
  15. 15.
    Whittaker JA, Griffith IP. Recurrent laryngeal nerve paralysis in patients receiving vincristine and vinblastine. Br Med J. 1977;1:1251–2.PubMedCrossRefGoogle Scholar
  16. 16.
    Rezvani K, Bain BJ, Coulter CA. Loss of singing ability caused by vincristine. Clin Lab Haematol. 1998;20(1):47–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Anghelescu DL, De Armendi AJ, Thompson JW, Sillos EM, Pui CH, Sandlund JT. Vincristine induced vocal cord paralysis in an infant. Paediatr Anaesth. 2002;12:168–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Jeng MR, Feusner J. Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2001;18:137–42.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Serkan Feyyaz Yalin
    • 1
  • Sinan Trabulus
    • 1
  • Ayse Serap Yalin
    • 2
  • Gulsah Yenidunya Yalin
    • 1
  • Seniz Ongoren
    • 3
  • Mehmet Riza Altiparmak
    • 1
    Email author
  1. 1.Department of Internal Medicine, Cerrahpasa Medical FacultyIstanbul UniversityIstanbul, FatihTurkey
  2. 2.Department of Internal MedicineMarmara University Medical FacultyIstanbulTurkey
  3. 3.Department of Internal Medicine, Division of Hematology, Cerrahpasa Medical FacultyIstanbul UniversityIstanbul, FatihTurkey

Personalised recommendations